



Metrion Biosciences appoints Dr Benedetta Montagnini as Head of European Business Development

Expansion of European business development team supports next phase of growth for Metrion's ion channel drug discovery services

Cambridge, UK, 09 June 2022 - Metrion Biosciences Limited ("Metrion"), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Benedetta Montagnini as Head of European Business Development. Driven by the uptake of its ion channel discovery services, the appointment follows the recent creation of a Client Services team as Metrion expands its operations and enhanced drug discovery capabilities, internationally.

Based in Rome, Italy, Dr Montagnini will provide local support to Metrion's existing client base across Europe and Israel, along with leading the development of new business opportunities in the ion channel field. With over 20 years' experience working within the drug discovery services environment, Dr Montagnini was previously Business Development Manager at Eurofins Discovery and DiscoverX and prior to that Account Manager for the Industrial BioProcessing Division at Invitrogen. She holds a Bachelor's degree in Molecular Biology and a PhD *Magna cum Laude* in Biochemistry from Sapienza Università di Roma.

Nick Foster, Chief Commercial Officer of Metrion Biosciences, said: *"It is a pleasure to welcome Benedetta to the Metrion team. Engaging with and supporting our clients, locally and internationally, is Metrion's top priority and this exciting development enables us to enhance our ability to provide local support in Europe. Benedetta's appointment and the continuing expansion of our team of scientists, celebrates the Company's success and gives us a strong footing for our future growth in these regions."*

Dr Benedetta Montagnini, Head of European Business Development at Metrion Biosciences, commented: *"Metrion's continued growth substantiates its position as a leading provider of drug discovery research services for ion channel targets across a broad range of therapeutic areas. This reputation attracted me to the Company and I am delighted to be joining the team at this point in its expansion. I look forward to working with both existing and new clients and supporting the community across Europe. I have a great respect for Metrion's strong scientific focus for ion channel drug discovery and vision for the future development of its services"*

-ENDS-

Notes to Editors

	
Nick Foster Chief Commercial Officer, Metrion Biosciences	Dr Benedetta Montagnini Head of European Business Development, Metrion Biosciences

For high resolution images please contact Zyme Communications

Media contact:

Lily Jeffery
Zyme Communications
E-mail: lily.jeffery@zymecommunications.com
Tel: +44 (0)7891 477 378

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please [click here](#).

About Metrion Biosciences

Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences' ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages.

For more information, please visit www.metrionbiosciences.com
LinkedIn: [@metrion-biosciences](#) | Twitter: [@metrion_biosci](#)